日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force

卫生技术评估指南制定良好实践:国际卫生技术评估协会、HTAsiaLink 和 ISPOR 特别工作组报告

Botwright, Siobhan; Sittimart, Manit; Chavarina, Kinanti Khansa; Bayani, Diana Beatriz Samson; Merlin, Tracy; Surgey, Gavin; Suharlim, Christian; Espinoza, Manuel A; Culyer, Anthony J; Oortwijn, Wija; Teerawattananon, Yot

Expanding access to high-cost medicines under the Universal Health Coverage scheme in Thailand: review of current practices and recommendations

在泰国全民健康覆盖计划下扩大高价药品的可及性:现状回顾与建议

Butani, Dimple; Faradiba, Dian; Dabak, Saudamini Vishwanath; Isaranuwatchai, Wanrudee; Huang-Ku, Evan; Pachanee, Kumaree; Soboon, Budsadee; Culyer, Anthony J; Teerawattananon, Yot

Distributional Cost-Effectiveness Analysis Comes of Age

分配成本效益分析日趋成熟

Cookson, Richard; Griffin, Susan; Norheim, Ole F; Culyer, Anthony J; Chalkidou, Kalipso

Charging for the use of survey instruments on population health: the case of quality-adjusted life years

对人口健康调查工具的使用收费:以质量调整生命年为例

Teerawattananon, Yot; Luz, Alia Cg; Culyer, Anthony; Chalkidou, Kalipso

Building Capacity for Evidence-Informed Priority Setting in the Indian Health System: An International Collaborative Experience

在印度卫生系统中构建循证优先事项设定能力:一项国际合作经验

Downey, L E; Dabak, S; Eames, J; Teerawattananon, Y; De Francesco, M; Prinja, S; Guinness, L; Bhargava, B; Rajsekar, K; Asaria, M; Rao, N V; Selvaraju, V; Mehndiratta, A; Culyer, A; Chalkidou, K; Cluzeau, F A

What next after GDP-based cost-effectiveness thresholds?

在基于GDP的成本效益阈值之后,下一步是什么?

Chi, Y-Ling; Blecher, Mark; Chalkidou, Kalipso; Culyer, Anthony; Claxton, Karl; Edoka, Ijeoma; Glassman, Amanda; Kreif, Noemi; Jones, Iain; Mirelman, Andrew J; Nadjib, Mardiati; Morton, Alec; Norheim, Ole Frithjof; Ochalek, Jessica; Prinja, Shankar; Ruiz, Francis; Teerawattananon, Yot; Vassall, Anna; Winch, Alexander

National Institute for Health and Care Excellence, social values and healthcare priority setting

英国国家健康与护理卓越研究院、社会价值观和医疗保健优先事项设定

Littlejohns, Peter; Chalkidou, Kalipso; Culyer, Anthony J; Weale, Albert; Rid, Annette; Kieslich, Katharina; Coultas, Clare; Max, Catherine; Manthorpe, Jill; Rumbold, Benedict; Charlton, Victoria; Roberts, Helen; Faden, Ruth; Wilson, James; Krubiner, Carleigh; Mitchell, Polly; Wester, Gry; Whitty, Jennifer A; Knight, Selena

Expanding HTA - Correcting a Misattribution, Clarifying the Scope of HTA and CEA Comment on "Ethics in HTA: Examining the 'Need for Expansion'"

扩大卫生技术评估 (HTA)——纠正错误归因,澄清 HTA 和 CEA 的范围,评论“HTA 中的伦理:审视‘扩展的必要性’”

Culyer, Anthony J

How can we evaluate the cost-effectiveness of health system strengthening? A typology and illustrations

如何评估卫生系统强化措施的成本效益?类型学及实例分析

Hauck, K; Morton, A; Chalkidou, K; Chi, Y-Ling; Culyer, A; Levin, C; Meacock, R; Over, M; Thomas, R; Vassall, A; Verguet, S; Smith, P C

Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?

在迈向全民健康覆盖的道路上,卫生投资的经济评价:成本效益分析还是成本效果分析?

Culyer, Anthony J; Chalkidou, Kalipso